



Technology Offer

Ref.-No. M04/18

Cholesterol emulsion and supplementary food for the treatment of Smith-Lemli-Opitz syndrome

Introduction

The Smith-Lemli-Opitz syndrome is a hereditary autosomal recessive malformation syndrome based on a metabolic disorder of cholesterol biosynthesis. As a result, there is a deficiency of cholesterol and at the same time increase of 7-dehydrocholesterol (7-DHC), resulting in the affected patients with many health impairments.

The current standard therapy consists in the administration of cholesterol in water or oil, for example as a suspension. Due to the low solubility of cholesterol in both liquids, a sediment are often formed, whereby only a small part of the amount of cholesterol administered to the patient can be ingested and absorbed, while the majority of the cholesterol is excreted unused.

Therefore, there is a further need of cholesterol-containing compositions that can be used for an optimized intake of cholesterol.

Invention

The present technology offer relates to edible and probe able emulsions of particular composition and their use in medicine. Especially, for the treatment of diseases associated with a decreased cholesterol level, such as the Smith-Lemli-Opitz syndrome. Further, a process for producing such emulsions has been developed.



Cholesterol emulsion with (right) and without (left) food additives

Advantages of the invention

- Emulsions can be prepared to contain a defined amount of cholesterol.
- Properties of the emulsions can be adapted to the application according to the respective patient requirements.
- Lowering the 7-DHC level.
- High storage stability with cooling.

Patent situation

Patent application filed in Germany.

For further detailed information please contact:

Clinic Invent

Dr. Marion Willenborg
Albert-Schweitzer-Campus 1,
Building D3
D-48149 Münster, Germany

Tel. +49-(0)251/83 58 904

marion.willenborg@ukmuenster.de